# An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

> **NCT06073132** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **TWi Biotechnology, Inc.** · enrollment: 80 (estimated)

## Conditions studied

- Generalized Epidermolysis Bullosa Simplex

## Interventions

- **DRUG:** AC-203
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT06073132
- **Lead sponsor:** TWi Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-04
- **Primary completion:** 2026-09
- **Final completion:** 2027-03
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06073132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06073132, "An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06073132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*